Fungicidal effects of some derivatives of 2-ferrocenyl-benzimidazoles: A possible template for antifungal drug design

Journal of Medical Sciences

Volumn 8, Issue 8, 2008, Pages 673-681

  Abu Elteen, Khaled H ^a   Abdel Jalil, Raid J ^a,b   Hamad, Mawieh A ^a   Ghaleb, M ^a   Khen, Khalid M ^c   Voelter, W ^b  

^a HASHEMITE UNIVERSITY   (Jordan)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Antifungal susceptibility; Benzimidazoles derivatives; Candida sp; Drug design; Virulence factors

Indexed keywords

2 FERROCENYL 5 FLUORO 6 (4 METHYL 1 PIPERAZINYL)BENZIMIDAZOLE; 2 FERROCENYL 5 FLUORO 6 (4 PHENYL 1 PIPERAZINYL)BENZIMIDAZOLE; 2 FERROCENYL 5 FLUORO 6[4 (4 FLUOROPHENYL) 1 PIPERAZINYL)BENZIMIDAZOLE; 2 FERROCENYLBENZIMIDAZOLE DERIVATIVE; 4 FLUORO 5 (4 METHYL 1 PIPERZINYL) 2 NITROANILINE; 4 FLUORO 5 (4 PHENYL 1 PIPERZINYL) 2 NITROANILINE; ANTIFUNGAL AGENT; BENZIMIDAZOLE DERIVATIVE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; FUNGAL CELL; FUNGAL STRAIN; FUNGUS GROWTH; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 67649543809     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2008.673.681     Document Type: Article

References (20)

1. Abdel-Jalil, R.J. and W. Voelter, 2005. Synthesis of new 2-ferrocenyl-5-fluoro-6-(4-substituted-1-piperazinyl)-1H-benzimidazoles of potential biological interest, J. Heterocyclic Chem., 42: 67-71.
2. Abu-Elteen, K.H., 2001. Increased incidence of vulvovaginal candidiasis caused by Candida glabrata in Jordan. Jap. J Infect Dis., 54: 103-107.
3. Abu-Elteen, K.H. and M. Hamad, 2005. Antifungal Agents for Use in Human Therapy. In: Fungi: Biology and Applications, Kavanagh, K. (Ed). Wiley and Sons, UK., 1, pp. 191-217.
4. Abu-Elteen, K.H. and M. Hamad, 2007. Novel Antifungal Therapies. In: New Insights in Medical Mycology, Kavanagh, K. (Ed.). Springer, The Netherlands, pp: 69-98.
5. Abu-Elteen, K.H., 2000, Effects of date extract on adhesion of Candida species to human buccal epithelial cells in vitro. J. Oral Pathol. Med., 29: 200-205.
6. Abu-Elteen, K.H., M. Hamad and K. Kavanagh, 2007. Epsilometer test-based determination of susceptibility of clinically important Candida isolates to conventional antifungal agents. J. Med. Sci., 7: 374-382.
7. Andriole, V.T., 1999. Current and future antifungal therapy: New targets for antifungal agents. J. Antimicrob. Chemother., 44: 151-162.
8. Bartlett, M.S., T.D. Edline, M.M. Shaw and L.J. Wheat, 1998. Carbendazim cures histoplasmosis in mice. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept. 24-27, American Society for Microbiology, San Diego, CA, J58 Washington DC. USA., pp: 467-468.
9. Bodey, G., M. Mardani, H. Hanna, M. Boktour and J. Abbas et al., 2002. The epidemiology of Candida glabrata fungemia in immunocompromised patients with cancer. Am. J. Med., 112: 380-385.
10. Boykin, D.W., A. Kumar, G. Xiao, W.D. Wilson and B.C. Bender et al., 1998. 2,5-Bis[4-(N-alkylamidino) phenl]furans as anti Pneumocystis carinii agents. J. Med. Chem., 41: 124-129.
11. Del Poeta, M., A.S. Bixel, F. Barchiesi, R.R. Tidwell, D. Boykin, G. Scalise and J.R. Perfect 1999. In vitro activity of dicationic aromatic compounds and fluconazole against Cryptococous neoformans and Candida sp. J. Antimicrob. Chemother., 44: 223-228.
12. Del Poeta, M., W.A. Schell, C.C. Dykstra, S.J. Jones and R.R. Tidwell et al., 1998a. In vitro antifungal activities of a series of dications-substituted caibazoles, furans and benzimidazoles. Antimicrob. Agents Chemother., 42: 2503-2510.
13. Del Poeta, M., W.A. Schell, C.C. Dykstra, S.J. Jones and R.R. Tidwell et al., 1998b. Structure-in vitro activity relationships of pentamidine analogues and dication-substitutes bis-benzimidazoles as new antifungal agents. Antimlcrob. Agents Chemothers., 42: 2495-2502.
14. Ghannom, M.A. and L.B. Rice, 1999. Antifungal agents: Mode of action, mechanisms of resistance and clinical correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev., 12: 501-517.
15. Ghannoum, M.A., K.H. Abu-Elteen, M., Ellabib and P.A. Whittaker, 1990. Antimycotic effects of octenidine and pirtenidine. J. Antimicrob. Chemother., 25: 237-245.
16. Krcmery, V. and A.J. Barnes, 2002. Non-olbicans Candida sp. causing fungemia: Pathogenicity and antifungal resistance. J. Hosp. Infect., 50: 243-260.
17. Roilides, E., J. Dotis and A. Katragkou, 2007. Fusarium and Scedosporium: Emerging Fungal Pathogens. In: New Insights in Medical Mycology, Kavanagh, K. (Ed.). Springer, The Netherlands, pp: 267-285.
18. Safdar, A., V. Chaturvedi, E.W. Cross, S. Park, E.M. Bernard, D. Armstrong and D. Perlin, 2001. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob. Agents Chemother., 45: 2129-2133.
19. Sampathkumar, P. and C.V. Paya, 2001. Fusarium infection after solid organ transplantation. Clin. Infect. Dis., 32: 1237-1240.
20. Speller, D.C.E., 1980. Other Antifungal Agents. In: Antifungal Chemotherapy, Speller, D.C.E. (Ed). John Wiley Chichester, UK., pp: 183-210.